within Pharmacolibrary.Drugs.ATC.D;

model D01AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 500000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D01AA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nystatin is a polyene antifungal medication primarily used for the treatment of candidiasis of the skin, oral cavity, and gastrointestinal tract. It is not absorbed from the gastrointestinal tract or intact skin and is mainly used topically or orally (for local action). Nystatin is approved for medical use and is commonly used today for superficial fungal infections.</p><h4>Pharmacokinetics</h4><p>Nystatin administered orally in healthy adults. It is not systemically absorbed, and thus, pharmacokinetic parameters such as bioavailability, volume of distribution, and clearance are not measurable in plasma. Used for local action in the GI tract.</p><h4>References</h4><ol><li><p>Schäfer-Korting, M, et al., &amp; Korting, HC (1996). Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. <i>Mycoses</i> 39(9-10) 329–339. DOI:<a href=\"https://doi.org/10.1111/j.1439-0507.1996.tb00149.x\">10.1111/j.1439-0507.1996.tb00149.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9009654/\">https://pubmed.ncbi.nlm.nih.gov/9009654</a></p></li><li><p>Knowles, S, et al., &amp; Shear, NH (1994). Metronidazole hypersensitivity. <i>The Annals of pharmacotherapy</i> 28(3) 325–326. DOI:<a href=\"https://doi.org/10.1177/106002809402800305\">10.1177/106002809402800305</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8193418/\">https://pubmed.ncbi.nlm.nih.gov/8193418</a></p></li><li><p>de Aguiar, MM, et al., &amp; Holandino, C (2010). Oral sustained release nystatin tablets for the treatment of oral candidiasis: formulation development and validation of UV spectrophotometric analytical methodology for content determination. <i>Drug development and industrial pharmacy</i> 36(5) 594–600. DOI:<a href=\"https://doi.org/10.3109/03639040903384729\">10.3109/03639040903384729</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19954405/\">https://pubmed.ncbi.nlm.nih.gov/19954405</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D01AA01;
